Help patients say 'yes' to more moments

  • Significantly fewer affected days from Baseline with AJOVY® vs placebo with both monthly and quarterly doses1-3

    (Primary endpoint)

    Click below to select the data:

  • AJOVY® can help patients cut affected days by half or more from Baseline1-3

    (Secondary endpoint)

    Click below to select the data:

With AJOVY®, patients may experience significantly 
fewer affected days from Baseline vs placebo1-3

In episodic migraine, a reduction in monthly migraine days was demonstrated during the 12-week period (primary endpoint), with results seen as early as Week 11,2

EPISODIC MIGRAINE
MEAN REDUCTION FROM BASELINE IN AVERAGE MONTHLY MIGRAINE DAYS1,2

In chronic migraine, a reduction in monthly headache days of at least moderate severity was demonstrated during the 12-week period (primary endpoint), with results seen as early as Week 11,3

CHRONIC MIGRAINE
MEAN REDUCTION FROM BASELINE IN AVERAGE MONTHLY HEADACHE DAYS OF AT LEAST MODERATE SEVERITY1,3

Secondary endpoints:

Give patients the chance to cut affected days
by half or more with AJOVY®1-3

EPISODIC MIGRAINE

PATIENTS ACHIEVING ≥50% REDUCTIONS FROM BASELINE IN MONTHLY AVERAGE MIGRAINE DAYS1,2

Episodic Migraine
PATIENTS ACHIEVING ≥50% REDUCTIONS FROM BASELINE IN MONTHLY AVERAGE MIGRAINE DAYS1,2
Chronic Migraine
PATIENTS ACHIEVING ≥50% REDUCTIONS FROM BASELINE IN MONTHLY AVERAGE HEADACHE DAYS OF AT LEAST MODERATE SEVERITY1,3
Chronic Migraine
PATIENTS ACHIEVING ≥50% REDUCTIONS FROM BASELINE IN MONTHLY AVERAGE HEADACHE DAYS OF AT LEAST MODERATE SEVERITY1,3

Help patients say 'yes' to more moments at work, in study and at home

AJOVY® significantly reduced the disabling effects of migraine2-5

In episodic migraine, patients treated with AJOVY® experienced 60% average improvement in MIDAS score from Baseline2 in:

  • Attendance and productivity at work5

  • Ability to do household work5

  • Attendance at family, social, and leisure activities5

(vs 47% with placebo, p<0.01)2
Mean reductions from Baseline* in MIDAS score were -24.6 with AJOVY® monthly, -23.0 with AJOVY® quarterly, and -17.5 with placebo.2

In chronic migraine, over 60% of patients treated with AJOVY® experienced clinically meaningful improvements from Baseline4 in:

  • Frequency and severity of headache pain5

  • Ability to perform daily tasks5

  • Mood, concentration, and fatigue5

(vs 53% with placebo, p<0.03)4
Mean change from Baseline in HIT-6 score was -6.8 with AJOVY® monthly, -6.4 with AJOVY® quarterly and -4.5 with placebo.3 A clinically meaningful improvement in patients with chronic daily headache is defined as at least a 2.3-point reduction in HIT-6 score.5

Suggestions to explore next

Continue to Dosing flexibility page of AJOVY

Flexibility to help meet your patients' needs1

dosing options for ajovy®

AJOVY® was evaluated for registration in two Phase III clinical trials (the HALO studies)1-3

Clinical trial designs
Continue to Safety page of AJOVY

A generally well-tolerated treatment choice1-3

safety profile for ajovy®